How to Buy Deciphera Pharmaceuticals Stock
Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.
Deciphera Pharmaceuticals stock last closed at $25.28, up 72.56% from the previous day, and has increased 74.71% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.82 percentage points. Deciphera Pharmaceuticals stock is currently +155.35% from its 52-week low of $9.90, and -0.47% from its 52-week high of $25.40.
At the moment, there are 80.8M shares of DCPH outstanding. The market value of DCPH is $2.04B. In the past 24 hours, 50.72M DCPH shares were traded.
How to Buy Deciphera Pharmaceuticals Stock
Not sure how to invest in Deciphera Pharmaceuticals stock? Here's how.
- Decide where to buy Deciphera Pharmaceuticals stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you choose where to buy Deciphera Pharmaceuticals stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit money your brokerage account: Choose your method of payment and add your information.
- Analyze Deciphera Pharmaceuticals stock: The Deciphera Pharmaceuticals ticker symbol is DCPH. Is Deciphera Pharmaceuticals stock a good investment? Should you buy shares of DCPH? How do DCPH's underlying business fundamentals look? Do top analysts think Deciphera Pharmaceuticals is a good buy? Why has DCPH's stock price moved recently? (Hint: Our stock market research tools can help you figure out if DCPH is a good stock to buy).
- Make your DCPH trade: Decide if you will purchase DCPH shares at the current market price or use a limit order to buy DCPH stock at a specific price.
- Get the latest scoop on your investment in DCPH: Create a watchlist to keep track of your position in Deciphera Pharmaceuticals stock.
Step 1: Decide where to buy Deciphera Pharmaceuticals stock
You need a brokerage account to access the NASDAQ market and buy DCPH shares.
Our favorite brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Tech to Healthcare, New York to London — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro now.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal details so you are able to invest in DCPH today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create your new brokerage account.
- Send your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you've created your account on stock market apps, you can securely and quickly fund your account:
Watch the tutorial below for more details depositing money into your investment account.
Step 4: Analyze Deciphera Pharmaceuticals stock
After you have identified the best place to buy Deciphera Pharmaceuticals stock, it's important to research their stock prior to investing, so you can comprehend the risk as well as the upside.
Overview of key DCPH info
DCPH Due Diligence Checks
WallStreetZen was built to help part-time investors do better fundamental analysis quickly.
You can view all of the due diligence checks on DCPH's stock page.
What is the fair value of DCPH stock?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge DCPH's true value.
Using relative valuations ratios:
- DCPH may be overvalued based on its P/B ratio of 5.82x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 2.12x
You can do additional valuation analysis on DCPH's stock here.
A quick look at DCPH Financials
Pros:
- There are more short-term assets than long-term liabilities on the DCPH balance sheet.
- DCPH has a low debt to equity ratio of 0.35.
- DCPH has $306.22M in cash and short term investments. This is enough to cover its annual cash burn of $147.48M.
- There are more short-term assets than short-term liabilities on the DCPH balance sheet.
- DCPH has cash burn of 147475000. It has enough cash and short-term investments to cover this for at least one year.
Cons:
- Total DCPH debt is higher than 5 years ago, relative to shareholder equity.
- DCPH profit margin has gone up by 0.14 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy Deciphera Pharmaceuticals stock, according to analysts?
Out of 6 Equities analysts who give forecasts on DCPH, the consensus analyst rating on DCPH is a Buy
Please note that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest DCPH Analyst Recommendations
Christopher Raymond, a top 12% analyst from Piper Sandler upgrades DCPH to a strong buy rating and raises their DCPH price target from $18.00 to $23.00, on Oct 30, 2023.
Piper Sandler's Christopher Raymond upgraded their rating on Deciphera Pharmaceuticals (NASDAQ: DCPH) from Hold to Strong Buy on 2023/10/30. The analyst also raised their price target by 27.8% from $18 to $23.
The analyst said they made the move to reflect Deciphera's positive top-line results from the MOTION pivotal Phase 3 study of vimseltinib in patients with tenosynovial giant cell tumor* (TGCT) not amenable to surgery.
Given the results, the drug will likely perform better than previously expected, Raymond predicted.
With Qinlock's** "steady and solid traction" in earlier lines of GIST, "investors should buy the stock when it's approaching $23," the analyst recommended.
Footnotes
* Tenosynovial Giant Cell Tumor (TGCT) is a group of typically benign lesions arising from the synovium of joints, bursae and tendon sheaths. Depending on their growth pattern and clinical course, they are divided into localized and diffuse types. [from here]
** Qinlock is a prescription medicine used to treat adults with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitor medicines, including imatinib, for their GIST. [from here]
You can dive deeper into what analysts are saying on the Deciphera Pharmaceuticals stock forecast page.
DCPH Trading Indicators
Is DCPH Making Money?
Last year, DCPH revenue was $163.36M. During the last 4 year, DCPH's revenue has grown by 59.88% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 30.28%.
Dig into DCPH's earnings and revenue performance here.
What are DCPH insiders up to?
Over the last year, executives and large shareholders at DCPH have bought more shares than they have sold.
Brightstar Associates LLC, 10% Owner of DCPH, was the latest DCPH insider to buy. They bought $481.36 worth of DCPH shares on Apr 22, 2024.
Research more about who owns DCPH stock here.
Does DCPH provide a stable income stream?
No, Deciphera Pharmaceuticals doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your DCPH trade
There are two main options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly fine. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at an exact price, use a limit order.
Hit the Open Trade button and eToro will execute your order.
If you need more help buying stocks on eToro, watch the how to video below:
Step 6: Get the latest scoop on your investment in DCPH
Now that you own some DCPH stock, you'll want to keep up with your shares.
Start a watchlist to track the most important metrics related to your DCPH stock.
DCPH Feed
How to Buy Stock in Deciphera Pharmaceuticals
To summarize, here are the 6 steps to buy stock in Deciphera Pharmaceuticals:
- Decide where to buy Deciphera Pharmaceuticals stock
- Create your brokerage account
- Deposit money your brokerage account
- Analyze Deciphera Pharmaceuticals stock
- Make your DCPH trade
- Get the latest scoop on your investment in DCPH
If you require a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get notifications regarding your investment in Deciphera Pharmaceuticals, create a watchlist today.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.